These results suggest other molecular mechanisms driving oncogenic NF-κB in EBV + DLBCL, as previous analyses indicated that EBV + DLBCLs are characterized by activation of NF-κB signaling [4, 40]. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.